WO1996034943A1 - 12-lipoxygenase leucocytaire humaine et son role dans la pathogenese d'etats pathologiques - Google Patents

12-lipoxygenase leucocytaire humaine et son role dans la pathogenese d'etats pathologiques Download PDF

Info

Publication number
WO1996034943A1
WO1996034943A1 PCT/US1996/006328 US9606328W WO9634943A1 WO 1996034943 A1 WO1996034943 A1 WO 1996034943A1 US 9606328 W US9606328 W US 9606328W WO 9634943 A1 WO9634943 A1 WO 9634943A1
Authority
WO
WIPO (PCT)
Prior art keywords
human
patient
lipoxygenase
expression
cells
Prior art date
Application number
PCT/US1996/006328
Other languages
English (en)
Inventor
Jerry L. Nadler
Rama Natarajan
Original Assignee
City Of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City Of Hope filed Critical City Of Hope
Priority to AU56377/96A priority Critical patent/AU706241B2/en
Priority to JP8533570A priority patent/JPH11511004A/ja
Priority to US08/945,744 priority patent/US6191169B1/en
Priority to EP96913354A priority patent/EP0824583A1/fr
Publication of WO1996034943A1 publication Critical patent/WO1996034943A1/fr
Priority to US09/691,845 priority patent/US6486181B1/en
Priority to US09/739,843 priority patent/US6893829B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)

Abstract

Selon la présente invention, l'on a obtenu des indications de la présence d'une 12-lipoxygénase (12-LO) du type leucocytaire humain et du rôle qu'elle joue dans la pathogenèse de plusieurs états ou processus pathologiques importants, dont l'athérosclérose, le cancer du sein, les maladies inflammatoires et auto-immunes, les affections rénales et vasculaires diabétiques et l'insulinorésistance. La médiation, ainsi que l'inhibition, de l'activation enzymatique ou de l'expression de la 12-LO leucocytaire constitue un nouveau traitement permettant de prévenir ou de soigner ces états pathologiques.
PCT/US1996/006328 1992-08-28 1996-05-03 12-lipoxygenase leucocytaire humaine et son role dans la pathogenese d'etats pathologiques WO1996034943A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU56377/96A AU706241B2 (en) 1995-05-04 1996-05-03 Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
JP8533570A JPH11511004A (ja) 1995-05-04 1996-05-03 ヒト白血球１２−リポキシゲナーゼおよび疾病状態の病因でのその役割
US08/945,744 US6191169B1 (en) 1992-08-28 1996-05-03 Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
EP96913354A EP0824583A1 (fr) 1995-05-04 1996-05-03 12-lipoxygenase leucocytaire humaine et son role dans la pathogenese d'etats pathologiques
US09/691,845 US6486181B1 (en) 1992-08-28 2000-10-18 Human leukocutye 12-lipoxygenase and its role in the pathogenesis of disease states
US09/739,843 US6893829B2 (en) 1992-08-28 2000-12-20 Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43468195A 1995-05-04 1995-05-04
US08/434,681 1995-05-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US43468195A Continuation-In-Part 1992-08-28 1995-05-04

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US08945744 A-371-Of-International 1996-05-03
US08/945,744 Continuation-In-Part US6191169B1 (en) 1992-08-28 1996-05-03 Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
US09/691,845 Division US6486181B1 (en) 1992-08-28 2000-10-18 Human leukocutye 12-lipoxygenase and its role in the pathogenesis of disease states
US09/739,843 Division US6893829B2 (en) 1992-08-28 2000-12-20 Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states

Publications (1)

Publication Number Publication Date
WO1996034943A1 true WO1996034943A1 (fr) 1996-11-07

Family

ID=23725230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/006328 WO1996034943A1 (fr) 1992-08-28 1996-05-03 12-lipoxygenase leucocytaire humaine et son role dans la pathogenese d'etats pathologiques

Country Status (5)

Country Link
EP (1) EP0824583A1 (fr)
JP (1) JPH11511004A (fr)
AU (1) AU706241B2 (fr)
CA (1) CA2220156A1 (fr)
WO (1) WO1996034943A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025598A2 (fr) * 1996-12-11 1998-06-18 Dana-Farber Cancer Institute Procedes et compositions pharmaceutiques inhibant la proliferation de cellules tumorales
WO1999009965A2 (fr) * 1997-08-21 1999-03-04 Takeda Chemical Industries, Ltd. Agent antiinflammatoire
WO1999018956A1 (fr) * 1997-10-15 1999-04-22 City Of Hope Inhibiteurs du recepteur de 12(s)-hete
WO1999027098A2 (fr) * 1997-11-21 1999-06-03 Genentech, Inc. Antigenes apparentes a a33 et leurs utilisations pharmacologiques
EP0953355A1 (fr) * 1996-05-31 1999-11-03 Sankyo Company, Limited Remede pour maladies auto-immunes
US6103496A (en) * 1998-05-29 2000-08-15 Vanderbilt University Isolated and purified 12R-lipoxygenase protein and nucleic acids
US6150371A (en) * 1996-05-31 2000-11-21 Sankyo Company, Limited Method for preventing and for treating autoimmune disease
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
WO2001048167A1 (fr) * 1999-12-27 2001-07-05 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, lipoxygenase 10, et polynucleotide codant pour ce polypeptide
WO2001068823A1 (fr) * 2000-03-15 2001-09-20 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, lipoxydase humaine 9, et polynucleotide codant pour ce polypeptide
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
WO2002102364A1 (fr) * 2001-06-18 2002-12-27 Yamada, Sachiko Preparations medicamenteuses agonistes ppar$g(g)
US6723506B2 (en) 2000-01-20 2004-04-20 Brigham And Women's Hospital Method of identifying PAX8-PPAR gamma-nucleic acid molecules
US7198917B2 (en) 1997-11-21 2007-04-03 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US9234024B2 (en) 2008-05-06 2016-01-12 Genentech, Inc. Affinity matured CRIg variants

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6112510B2 (ja) * 2013-04-09 2017-04-12 国立研究開発法人産業技術総合研究所 脂質酸化生成物の測定によるストレス、疲労の客観的評価方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005777A1 (fr) * 1992-08-28 1994-03-17 City Of Hope Inhibition de la formation ou de l'activite du processus de 12-lipoxygenase dans les leucocytes humains

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005777A1 (fr) * 1992-08-28 1994-03-17 City Of Hope Inhibition de la formation ou de l'activite du processus de 12-lipoxygenase dans les leucocytes humains
WO1995018609A1 (fr) * 1992-08-28 1995-07-13 City Of Hope 12-lipoxygenase de leucocytes humains, mediation exercee par la voie metabolique de cette enzyme et consequences de cette action

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVID BLEICH ET AL.: "Interleukin-1beta regulates the expression of a leukocyte type of 12-lipoxygenase in rat islets and RIN m5F cells", ENDOCRINOLOGY, vol. 136, no. 12, 1 December 1995 (1995-12-01), pages 5736 - 5744, XP000600977 *
JIA-LI GU ET AL.: "Evidence that a leukocyte type of 12-lipoxygenase is expressed and regulated by AngiotensinII in human adrenal glomerulosa cells", ENDOCRINOLOGY, vol. 134, no. 1, January 1994 (1994-01-01), pages 70 - 77, XP000601237 *
RAMA NATARAJAN ET AL.: "Elwvated glucose and angiotensin II increase 12-lopxygenase activity and expression in porcine aortic smooth muscle cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, June 1993 (1993-06-01), WASHINGTON US, pages 4947 - 4951, XP002013548 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953355A1 (fr) * 1996-05-31 1999-11-03 Sankyo Company, Limited Remede pour maladies auto-immunes
US6150371A (en) * 1996-05-31 2000-11-21 Sankyo Company, Limited Method for preventing and for treating autoimmune disease
EP0953355A4 (fr) * 1996-05-31 2002-02-27 Sankyo Co Remede pour maladies auto-immunes
JP2009063566A (ja) * 1996-12-11 2009-03-26 Dana-Farber Cancer Inst Inc 腫瘍細胞の成長を阻害するための方法および製薬学的組成物
JP4550133B2 (ja) * 1996-12-11 2010-09-22 ダナ−ファーバー キャンサー インスティテュート インク． 腫瘍細胞の成長を阻害するための方法および製薬学的組成物
US7635708B2 (en) 1996-12-11 2009-12-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
WO1998025598A3 (fr) * 1996-12-11 1998-07-30 Dana Farber Cancer Inst Inc Procedes et compositions pharmaceutiques inhibant la proliferation de cellules tumorales
EP1410799A1 (fr) * 1996-12-11 2004-04-21 Dana-Farber Cancer Institute Méthodes et composés pharmaceutiques pour inhiber la croissance des tumeurs
WO1998025598A2 (fr) * 1996-12-11 1998-06-18 Dana-Farber Cancer Institute Procedes et compositions pharmaceutiques inhibant la proliferation de cellules tumorales
JP2001510462A (ja) * 1996-12-11 2001-07-31 ダナ・フアーバー・キヤンサー・インスチチユート 腫瘍細胞の成長を阻害するための方法および製薬学的組成物
WO1999009965A3 (fr) * 1997-08-21 1999-05-20 Takeda Chemical Industries Ltd Agent antiinflammatoire
WO1999009965A2 (fr) * 1997-08-21 1999-03-04 Takeda Chemical Industries, Ltd. Agent antiinflammatoire
WO1999018956A1 (fr) * 1997-10-15 1999-04-22 City Of Hope Inhibiteurs du recepteur de 12(s)-hete
US6046224A (en) * 1997-10-15 2000-04-04 City Of Hope 12 (S)--hete receptor blockers
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
WO1999027098A2 (fr) * 1997-11-21 1999-06-03 Genentech, Inc. Antigenes apparentes a a33 et leurs utilisations pharmacologiques
WO1999027098A3 (fr) * 1997-11-21 1999-11-18 Genentech Inc Antigenes apparentes a a33 et leurs utilisations pharmacologiques
US6838554B2 (en) 1997-11-21 2005-01-04 Genetech, Inc. Nucleic acids encoding proteins that stimulate the proliferation of t-lymphocytes
US7115713B2 (en) 1997-11-21 2006-10-03 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US7198917B2 (en) 1997-11-21 2007-04-03 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US7211400B2 (en) 1997-11-21 2007-05-01 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US7273726B2 (en) 1997-11-21 2007-09-25 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US6103496A (en) * 1998-05-29 2000-08-15 Vanderbilt University Isolated and purified 12R-lipoxygenase protein and nucleic acids
US6569644B2 (en) 1998-05-29 2003-05-27 Vanderbilt University Isolated and purified 12R-lipoxygenase protein and nucleic acids
WO2001048167A1 (fr) * 1999-12-27 2001-07-05 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, lipoxygenase 10, et polynucleotide codant pour ce polypeptide
US6723506B2 (en) 2000-01-20 2004-04-20 Brigham And Women's Hospital Method of identifying PAX8-PPAR gamma-nucleic acid molecules
WO2001068823A1 (fr) * 2000-03-15 2001-09-20 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, lipoxydase humaine 9, et polynucleotide codant pour ce polypeptide
WO2002102364A1 (fr) * 2001-06-18 2002-12-27 Yamada, Sachiko Preparations medicamenteuses agonistes ppar$g(g)
US9234024B2 (en) 2008-05-06 2016-01-12 Genentech, Inc. Affinity matured CRIg variants

Also Published As

Publication number Publication date
EP0824583A1 (fr) 1998-02-25
AU5637796A (en) 1996-11-21
CA2220156A1 (fr) 1996-11-07
AU706241B2 (en) 1999-06-10
JPH11511004A (ja) 1999-09-28

Similar Documents

Publication Publication Date Title
AU706241B2 (en) Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
Tarpey et al. Skeletal muscle autophagy and mitophagy in endurance-trained runners before and after a high-fat meal
Zhang et al. Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome
Long et al. Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes
Wu et al. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes.
Sasaki et al. A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension
Ferrannini et al. Effect of fatty acids on glucose production and utilization in man.
Tripathy et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects
Hube et al. Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non‐insulin‐dependent diabetes mellitus
Mehrotra et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification
Derosa et al. Adipocytokine levels in obese and non-obese subjects: an observational study
Krook et al. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients.
Ropelle et al. Reversal of diet‐induced insulin resistance with a single bout of exercise in the rat: the role of PTP1B and IRS‐1 serine phosphorylation
Aroda et al. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action
Zingarelli et al. Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-γ ligands, 15-deoxy-Δ12, 14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-κB, heat shock factor 1, and AKT
US6893829B2 (en) Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
Wang et al. Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I receptor is decreased in sedentary chronic hemodialysis patients
Xing et al. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats
Rivera et al. Effect of valine on myotube insulin sensitivity and metabolism with and without insulin resistance
Zu et al. Salicylate blocks lipolytic actions of tumor necrosis factor-α in primary rat adipocytes
Han et al. Association between vitamin D deficiency and levels of renin and angiotensin in essential hypertension
US6060311A (en) Retinoid suppression of ventricular muscle cell hypertrophy
Wang et al. Renal 20-hydroxyeicosatetraenoic acid synthesis during pregnancy
US6486181B1 (en) Human leukocutye 12-lipoxygenase and its role in the pathogenesis of disease states
JP5165069B2 (ja) 虚血性心疾患危険群診断薬

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 08945744

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2220156

Country of ref document: CA

Ref country code: JP

Ref document number: 1996 533570

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2220156

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996913354

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996913354

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996913354

Country of ref document: EP